SNMMI continues advocacy on utility of amyloid imaging

03/27/2013 | MolecularImaging.net

SNMMI and the Alzheimer's Association will meet with CMS officials next month to discuss appropriate use criteria concerning the use of amyloid imaging in evaluating and diagnosing Alzheimer's disease. SNMMI President Frederic H. Fahey said SNMMI "will recommend coverage for the three indications specified by the AUC." Amyloid imaging is not currently reimbursed.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL